WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 384

Legislative bill overview

HB 384 relates to intranasal epinephrine (a nasal spray form of epinephrine used for severe allergic reactions). The bill's specific provisions are not detailed in the information provided, but it likely addresses authorization, distribution, training requirements, or liability protections for intranasal epinephrine use in Kentucky—possibly in schools, public spaces, or by laypersons.

Why is this important

Intranasal epinephrine offers an alternative to traditional intramuscular injectors (EpiPens) for treating anaphylaxis, potentially improving accessibility and ease of use during emergencies. Several states have passed legislation allowing non-medical personnel to carry and administer intranasal epinephrine in public settings, which could save lives in anaphylactic emergencies before emergency medical services arrive.

Potential points of contention

  • Regulatory clarity: Questions about FDA approval status, whether the bill authorizes currently-approved products or seeks to expand access beyond current federal guidelines
  • Liability and training requirements: Balancing accessibility against concerns about appropriate use, proper administration technique, and who bears responsibility for improper use
  • Cost and equity: Whether expanded access inadvertently favors institutions that can afford to stock intranasal epinephrine, potentially creating disparities in emergency preparedness across schools or communities

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.